ChristopherGAzzoliMDFASCO

Oncology • Providence, RI

Thoracic Cancer

Director of Thoracic Oncology, Lifespan Cancer Institute; Associate Professor of Medicine, Brown University

Join to view full profile

Dr. Azzoli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Azzoli's full profile

Already have an account?

Office
Lifespan Cancer Institute
593 Eddy Street, George 362
Providence, RI 02903
Fax+1 401-444-4184

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Johns Hopkins UniversityResidency, Internal Medicine, 1996 - 1999
Johns Hopkins University School of MedicineClass of 1996

Certifications & Licensure

RI State Medical License 2018 - 2026
MA State Medical License 2012 - 2025
NY State Medical License 1999 - 2013
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Boston Magazine Castle Connolly, 2013
Top Doctors: New York Metro Area Castle Connolly, 2012-2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
New York Magazine: Top Doctors Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC Start of enrollment: 2005 Nov 01
Completed
Phase 1
Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer Start of enrollment: 2003 Jan 01
Completed
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 2
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer Start of enrollment: 2008 May 01
Completed
Not Applicable
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) Start of enrollment: 2011 Oct 01
Completed
Phase 2
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy Start of enrollment: 2018 Jan 17
Completed
Not Applicable
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab Start of enrollment: 2021 Oct 05
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.
Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon
Oncotarget. 2025-03-12
TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury.
Jillian Strandberg, Anna Louie, Seulki Lee, Marina Hahn, Praveen Srinivasan
The Journal of Clinical Investigation. 2025-01-14
Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.
Suchitra Kamle, Bing Ma, Gail Schor, Madison Bailey, Brianna Pham
Translational Oncology. 2024-11-01

Journal Articles

Oxford University Press Has Registered This DOI Pre-Publication
R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press

Press Mentions

Roche’s IMpower010 Trial Results Warrant Evidence on Survival Impact for Tecentriq Adoption in Non-Small Cell Lung CancerJune 2nd, 2021
Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake BoostNovember 19th, 2019

Committees

Member (Steering committee), Update Committee of the ASCO NSCLC Expert Panel, American Society of Clinical Oncology 2015 - Present